- Home
- BILI vs IMVT Comparison
BILI vs IMVT Comparison
Compare BILI & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BILI | IMVT |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.5B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BILI | IMVT |
|---|---|---|
| Price | $15.18 | $37.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $31.13 | ★ $33.00 |
| AVG Volume (30 Days) | ★ 3.6M | 1.1M |
| Earning Date | 05-19-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.77 | N/A |
| Revenue Next Year | $9.59 | N/A |
| P/E Ratio | $122.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.39 | $14.86 |
| 52 Week High | $36.40 | $45.42 |
Technical Indicators
Market Signals| Indicator | BILI | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 37.25 |
| Support Level | N/A | $23.66 |
| Resistance Level | $19.10 | $41.22 |
| Average True Range (ATR) | 0.38 | 1.37 |
| MACD | -0.03 | -0.32 |
| Stochastic Oscillator | 38.58 | 18.82 |
Price Performance
Historical ComparisonAbout BILI Bilibili Inc.
Bilibili is a Chinese online entertainment platform best known for its YouTube-like video-sharing service. Founded in 2009, it initially focused on long-form content centered around anime, comics, and gaming, or ACG, catering primarily to Generation Z users. Over time, the platform has expanded its content ecosystem to cover a broader range of interests, successfully attracting a more diverse audience beyond its original Gen Z base.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.